UMLS - Terms starting with ‘F’

	Medical glossary.
	MEDINDEX.AM UMLS About Catalog. Medical sites. UMLS.Semantic Types. Feedback

%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z a c d e g h i

O O- O0 O1 O2 O3 OA OB OC OD OE OF OG OH OI OJ OK OL OM ON OO OP OR OS OT OU OV OW OX OY OZ

OFA OFB OFF OFI OFL

selected terms: 71

page 1 of 1

Of bypass graft of the extremities: [ ] (UMLS (ICD9CM) C0375300) =Disease or Syndrome
Ofatumumab: [A fully human, high-affinity IgG1 monoclonal antibody directed against CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 molecule on the surface of B-cells. CD20 antigen found on over 90% of B-cell lymphomas, as well as other lymphoid tumors of B-cell origin, acts as a calcium ion channel and regulates early steps in B lymphocyte activation. Following binding, ofatumumab triggers a complement-dependent cell lysis and antibody-dependent cell-mediated cytotoxicity on B-cells overexpressing CD20, thereby depleting and preventing the proliferation of these B-cells. ( NCI )] (UMLS (NCI) C1832027) =Pharmacologic Substance ;;
Off: [No longer planned or scheduled (said of events). ( NCI )] (UMLS (NCI) C1518543) =Qualitative Concept; ;;
Off Follow-up: [No longer participating in the follow-up phase of a study; not being followed. ( NCI )] (UMLS (NCI) C1518545) =Functional Concept; ;;
Off Protocol: [No longer participating in a study; not being followed and will not be retreated. ( NCI )] (UMLS (NCI) C1518546) Off Study;;Off-Protocol;;Off-Study;; =Qualitative Concept; ;;
Off Treatment: [When a patient is not receiving therapy they are considered off treatment. In clinical trials, a dosing schedule may require a patient to stop medication for a period of time, then resume, such as 28 days on and 7 days off. ( NCI )] (UMLS (NCI) C1518544) =Functional Concept; ;;
Off-Eazy 170 MG/ML Topical Solution: [ ] (UMLS (RXNORM) C0711913) Salicylic Acid 170 MG/ML Topical Solution [Off-Eazy];; =Clinical Drug
Office: (UMLS (HL7) C1547198) =Organization =Organization Unit Type;;
Office: (UMLS (HL7) C1549636) =Idea or Concept =Address type;;
Office for Protection from Research Risks: [The Office for Protection from Research Risks (OPRR) is organizationally located in the Office of the Director, NIH. OPRR is charged with interpreting and overseeing implementation of the regulations regarding the Protection of Human Subjects codified at Title 45, Part 46, of the Code of Federal Regulations. Also, OPRR is responsible for providing guidance on ethical issues in biomedical and behavioral research. ( NCI )] (UMLS (NCI) C1518547) OPRR;; =Health Care Related Organization; ;;
Office Manager: [An employee charged with the general administrative responsibilities of any given office of a corporation or business, responsible for all paperwork, including its filing and retention over time, and the supervision of office staff. ( NCI )] (UMLS (NCI) C0402335) =Professional or Occupational Group
Office of Budget and Financial Management: (UMLS (NCI) C1518549) =Organization; ;;
Office of Cancer Genomics: (UMLS (NCI) C1518550) =Health Care Related Organization; ;;
Office of Cancer Survivorship: [The Office of Cancer Survivorship was established in 1996 to provide support and a focus for research and other activities dealing with cancer survivors. OCS workshops were held in 1996 and 1997 to define priorities for research, which included the prevalence of physical effects from cancer treatment, the prevalence of second cancers in survivors, quality of life, and quality and cost of follow-up care for survivors. ( NCI )] (UMLS (NCI) C1518552) =Health Care Related Organization
Office of Centers, Training, and Resources: (UMLS (NCI) C1518553) =Organization
Office of Communications: [The Office of Communications encompasses the former Office of Cancer Communications, The Office of Liaison Activities, and the Office of Cancer Information, Communication and Education. Its mission is to communicate accurate information about cancer and NCI activities to a wide array of audiences, including: cancer patients, family members, health care providers, community health educators, advocates, Congress, the media, and the general public. ( NCI )] (UMLS (NCI) C1518554) =Organization
Office of International Affairs: (UMLS (NCI) C1518555) =Organization
Office of Legislative and Congressional Activities: (UMLS (NCI) C1518556) =Organization
Office of Liaison Activities: [Formed to act as a central point of contact and NCI link to cancer advocacy organizations. Recently rolled into the Office of Communications. ( NCI )] (UMLS (NCI) C1518557) =Health Care Related Organization
Office of Management: (UMLS (NCI) C1521841) =Organization
Office of Science Opportunity: (UMLS (NCI) C1518558) =Health Care Related Organization
Office of Science Planning and Analysis: (UMLS (NCI) C1518559) =Organization
Office of Special Populations Research: [The Office of Special Populations Research was established in 1996 to advise the Director of NCI and provide a focal point for leadership and coordination on minority and other special populations research. ( NCI )] (UMLS (NCI) C1518560) OSPR;; =Organization
Office of Technology and Industrial Relations: (UMLS (NCI) C1518561) =Organization
Office Phone Number: (UMLS (HL7) C1549621) =Idea or Concept =Preferred method of contact;;
Officers: (UMLS (HL7) C1549461) =Idea or Concept =Military Rank/Grade;;
official registry: [ Definition:The formal name as registered in an official (government) registry, but which name might not be commonly used. Particularly used in countries with a law system based on Napoleonic law. ( HL7V3.0 )] (UMLS (HL7) C1698061) =Intellectual Product ;; =EntityNameUse;;
Offset: [The distance between a point and a fixed reference point; difference between a set point and the actual reading. ( NCI )] (UMLS (NCI) C1711330) =Quantitative Concept ;;
Ofisolona: (UMLS (NCI) C1514373) =Steroid; Pharmacologic Substance
ofloxacin: [An antibiotic drug used to treat infection. It belongs to the family of drugs called quinolone antibiotics. ( NCI )] (UMLS (NCI) C0028902) =Organic Chemical; Antibiotic ;; =Heterocyclic Compounds, 3-Ring;;Piperazines;;[AM900] ANTI-INFECTIVES, OTHER;;[OP201] ANTIBACTERIALS, TOPICAL OPHTHALMIC;;[OT101] ANTIBACTERIALS, TOPICAL OTIC;; =levofloxacin;;OFLOXACIN 200 MG;;OFLOXACIN 300 MG;;OFLOXACIN 4 MG/ML;;OFLOXACIN 400 MG;;OFLOXACIN 0.3 %;;
OFLOXACIN 0.3 %: (UMLS (NDFRT)) (C1380896) =Clinical Drug =ofloxacin;; =OFLOXACIN 0.3% DROPS;;OFLOXACIN 0.3 %VV OPHTHALMIC SOLUTION
OFLOXACIN 0.3 %VV OPHTHALMIC SOLUTION: [ ] (UMLS (RXNORM) C0979107) OFLOXACIN 0.3 %WV OPHTHALMIC SOLUTION;;OFLOXACIN 0.3 %WW OPHTHALMIC SOLUTION;;OFLOXACIN 0.3% DROPS;;OFLOXACIN 0.3% Ophthalmic (non-systemic) solution;;OFLOXACIN 0.3% OPHTHALMIC DROPS;;OFLOXACIN 0.3% SOLN,OPH;;OFLOXACIN 3 %WV CONJUNCTIVAL SOLUTION;;OFLOXACIN 3 %WV OPHTHALMIC SOLUTION;;OFLOXACIN 3 MG OPHTHALMIC SOLUTION;;Ofloxacin 3 MG/ML Ophthalmic Solution;;OFLOXACIN0.3%OPHTHALMICDROPS =Clinical Drug =OFLOXACIN 0.3 %;;
OFLOXACIN 0.3-0.3% COMBINATION PACKAGE: [ ] (UMLS (RXNORM) C1361125) =Drug Delivery Device
OFLOXACIN 0.3% DROPS: [ ] (UMLS (RXNORM) C1354309) =Clinical Drug
OFLOXACIN 0.3% OINTMENT(GM): [ ] (UMLS (RXNORM) C1346124) OFLOXACIN 0.3% OINTMENT(GM) =Clinical Drug
Ofloxacin 100 MG: [ ] (UMLS (RXNORM) C1378403) =Clinical Drug
Ofloxacin 100 MG Oral Tablet: [ ] (UMLS (RXNORM) C1356321) OFLOXACIN 100MG TABLET;; =Clinical Drug
Ofloxacin 2 MG/ML: [ ] (UMLS (RXNORM) C1134854) =Clinical Drug
Ofloxacin 20 MG/ML: [ ] (UMLS (RXNORM) C0992674) =Clinical Drug
Ofloxacin 20 MG/ML [Floxin I.V.]: [ ] (UMLS (RXNORM) C1600411) =Clinical Drug
OFLOXACIN 200 MG: (UMLS (NDFRT)) (C0988255) =Clinical Drug =ofloxacin;; =OFLOXACIN 200 MG Oral (systemic) tablet
OFLOXACIN 200 MG Oral (systemic) tablet: [ ] (UMLS (RXNORM) C0689837) =Clinical Drug =OFLOXACIN 200 MG;;
Ofloxacin 200 MG [Floxin]: [ ] (UMLS (RXNORM) C1600415) =Clinical Drug
OFLOXACIN 20MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML): [ ] (UMLS (RXNORM) C0778369) Ofloxacin 20 MG/ML Injectable Solution;;ofloxacin 20 mg/ml intravenous solution;;OFLOXACIN 20MG/ML INJ;;OFLOXACIN 20MG/ML INTRAVEN. VIAL (SDV,MDV OR ADDITIVE) (ML);;OFLOXACIN 20MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML);;Ofloxacin IV Soln 20 MG/ML;;OFLOXACIN20MG/MLINTRAVEN.VIAL (SDV,MDV OR ADDITIVE) (ML);; =Clinical Drug
Ofloxacin 3 MG/ML: [ ] (UMLS (RXNORM) C1106001) =Clinical Drug
Ofloxacin 3 MG/ML [Floxin Otic]: [ ] (UMLS (RXNORM) C1607304) =Clinical Drug
Ofloxacin 3 MG/ML [Ocuflox]: [ ] (UMLS (RXNORM) C1600409) =Clinical Drug
Ofloxacin 30 MG/ML: [ ] (UMLS (RXNORM) C1968369) =Clinical Drug
Ofloxacin 30 MG/ML Otic Solution: [ ] (UMLS (RXNORM) C1966862) =Clinical Drug
OFLOXACIN 300 MG: (UMLS (NDFRT)) (C0988256) =Clinical Drug =ofloxacin;; =OFLOXACIN 300 MG Oral (systemic) tablet
OFLOXACIN 300 MG Oral (systemic) tablet: [ ] (UMLS (RXNORM) C0689838) =Clinical Drug =OFLOXACIN 300 MG;;
Ofloxacin 300 MG [Floxin]: [ ] (UMLS (RXNORM) C1600416) =Clinical Drug
OFLOXACIN 4 MG/ML: (UMLS (NDFRT)) (C0988257) =Clinical Drug =ofloxacin;; =OFLOXACIN 4MG/ML INTRAVENOUS SOLUTION
Ofloxacin 4 MG/ML [Floxin I.V.]: [ ] (UMLS (RXNORM) C1600410) =Clinical Drug
Ofloxacin 40 MG/ML: [ ] (UMLS (RXNORM) C0992675) =Clinical Drug
Ofloxacin 40 MG/ML [Floxin I.V.]: [ ] (UMLS (RXNORM) C1600412) =Clinical Drug
OFLOXACIN 400 MG: (UMLS (NDFRT)) (C0988258) =Clinical Drug =ofloxacin;; =OFLOXACIN 400 MG Oral (systemic) tablet
OFLOXACIN 400 MG Oral (systemic) tablet: [ ] (UMLS (RXNORM) C0689841) =Clinical Drug =OFLOXACIN 400 MG;;
Ofloxacin 400 MG [Floxin]: [ ] (UMLS (RXNORM) C1600417) =Clinical Drug
OFLOXACIN 40MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML): [ ] (UMLS (RXNORM) C0778370) Ofloxacin 40 MG/ML Injectable Solution;;ofloxacin 40 mg/ml intravenous solution;;OFLOXACIN 40MG/ML INJ;;OFLOXACIN 40MG/ML INTRAVEN. VIAL (SDV,MDV OR ADDITIVE) (ML);;OFLOXACIN 40MG/ML INTRAVENOUS VIAL (SDV,MDV OR ADDITIVE) (ML);;OFLOXACIN 40MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML);;Ofloxacin IV Soln 40 MG/ML;;OFLOXACIN40MG/MLINTRAVEN.VIAL (SDV,MDV OR ADDITIVE) (ML) =Clinical Drug
OFLOXACIN 4MG/ML INTRAVENOUS SOLUTION: [ ] (UMLS (RXNORM) C0982681) OFLOXACIN 4MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML);;Ofloxacin 4 MG/ML Injectable Solution;;ofloxacin 4 mg/ml intravenous solution;;OFLOXACIN 4MG/ML INJ;;OFLOXACIN 4MG/ML INTRAVENOUS SOLUTION;;OFLOXACIN 4MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML);;OFLOXACIN 4MG/ML/D5W INJ,BAG,50ML;;Ofloxacin in D5W 4 MG/ML;;OFLOXACIN/DEXTROSE 5%-WATER 4MG/ML INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER 200MG/50ML INTRAVEN. INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER 400MG/0.1L INTRAVEN. INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER 4MG/ML INTRAVEN. INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER 4MG/ML INTRAVENOUS INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER 4MG/ML INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER200MG/50MLINTRAVEN.INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER400MG/0.1LINTRAVEN.INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/DEXTROSE 5%-WATER4MG/MLINTRAVEN.INTRAVENOUS SOLUTION, PIGGYBACK (ML) =Clinical Drug =DEXTROSE 5 %;;OFLOXACIN 4 MG/ML
Ofloxacin 5 MG/ML: [ ] (UMLS (RXNORM) C1378501) =Clinical Drug
Ofloxacin 5 MG/ML Injectable Solution: [ ] (UMLS (RXNORM) C1342968) OFLOXACIN/SODIUM 200MG/40ML INTRAVENOUS SOLUTION, PIGGYBACK (ML);;OFLOXACIN/SODIUM 200MG/40ML INTRAVENOUS SOLUTION, PIGGYBACK (ML) =Clinical Drug
OFLOXACIN HCL 100MG INTRAVENOUS SOLUTION: [ ] (UMLS (RXNORM) C1343347) OFLOXACIN HCL 100MG INTRAVENOUS SOLUTION =Clinical Drug
Ofloxacin Injectable Solution: [ ] (UMLS (RXNORM) C1251322) =Clinical Drug
Ofloxacin Ophthalmic Solution: [ ] (UMLS (RXNORM) C1251626) =Clinical Drug
Ofloxacin Ophthalmic Solution [Ocuflox]: [ ] (UMLS (RXNORM) C1237661) =Clinical Drug
Ofloxacin Oral Tablet: [ ] (UMLS (RXNORM) C1247203) =Clinical Drug
Ofloxacin Oral Tablet [Floxin]: [ ] (UMLS (RXNORM) C1242759) =Clinical Drug
Ofloxacin Otic Solution: [ ] (UMLS (RXNORM) C1251677) =Clinical Drug
Ofloxacin Otic Solution [Floxin Otic]: [ ] (UMLS (RXNORM) C1239269) =Clinical Drug

UMLS

MEDINDEX.AM

to main page

About • Catalog. Medical sites. • UMLS.Semantic Types. • Feedback

top of page